Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|October 14, 2024

Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer

Author(s)Fred Saad, CQ, MD, FRCS, FCAHS

Key Takeaways

Darolutamide's structure limits blood-brain barrier penetration, reducing central nervous system side effects and improving safety.
It effectively delays metastasis and prolongs survival in non-metastatic castration-resistant prostate cancer.
Minimal drug-drug interactions make darolutamide suitable for patients with comorbidities or on multiple medications.

SHOW MORE

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how darolutamide offers potential advantages over other androgen receptor–targeted therapies for metastatic prostate cancer, including its unique molecular structure, favorable safety profile, and efficacy in specific clinical scenarios.

Episodes in this series

1 KOL is featured in this series.

EP. 1 Therapeutic Combination Therapies for Metastatic Prostate Cancer

1 KOL is featured in this series.

EP. 2 Patient-Centered Approach to Use of Chemotherapy in Metastatic Prostate Cancer

1 KOL is featured in this series.

EP. 3 Inclusion of Chemotherapy and Impact on Outcomes From the ARASENS Trial

1 KOL is featured in this series.

EP. 4 Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer

1 KOL is featured in this series.

EP. 5 Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer

1 KOL is featured in this series.

EP. 6 Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC

1 KOL is featured in this series.

EP. 7 Insights From ARANOTE and Clinical Practice

1 KOL is featured in this series.

EP. 8 The Evolving Role of Radium-223 in mCRPC and the Impact of Combination Therapies

1 KOL is featured in this series.

EP. 9 Radium-223 and Enzalutamide: Game-Changing PEACE III Phase 3 Data in mCRPC

1 KOL is featured in this series.

EP. 10 Genetic Testing in Metastatic Prostate Cancer: Key Insights on Germline and Somatic Mutations

1 KOL is featured in this series.

EP. 11 PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies

1 KOL is featured in this series.

EP. 12 Key Trials on PARP Inhibitor Combinations in Metastatic Prostate Cancer: Efficacy and Future Considerations

Video Content above is prompted by the following:

What are some of the benefits of darolutamide over other androgen receptor–targeted therapies?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

Experts urge FDA to revisit labeling for testosterone replacement therapy in men

FDA approves first-line Zenflow system for the treatment of BPH

© 2025 MJH Life Sciences^®

All rights reserved.